Table 1.
Study visit | Time (months) | Actions/documentation | Documented by | |
---|---|---|---|---|
INV | PAT | |||
Admission/treatment initiation | 0 | Allergy history–clinical manifestations | x | |
Allergy history–allergies in need of treatment | x | |||
Symptoms/symptomatic medication intake (during the last grass pollen season) | x | |||
Diagnostic tests | x | |||
Concomitant diseases/medication | x | |||
Documentation of date of first SLIT dose taken under medical supervision (30 min) | x | |||
QUARTIS questionnaire (Q1) | x | |||
Follow-up prescriptions (optional) | 1–4 | Adverse events/side effects | x | |
Receipt of follow-up prescription | x | |||
Booking of follow-up/control appointment | x | |||
QUARTIS questionnaire (Q2) | x | |||
Post-treatment visit | 5–6 (approximately) | Documentation of date | x | x |
Date of last intake | x | x | ||
Treatment conduct (titration/dose) | x | x | ||
Symptoms/symptomatic medication intake (during the grass pollen season) | x | |||
Patient well-being | x | x | ||
Tolerability | x | x | ||
Adverse events/side effects | x | |||
Date and reason for premature termination of treatment if applicable | x | |||
Continuation of treatment | x | |||
QUARTIS questionnaire (Q2) | x |
INV investigators, PAT patients, Q questionnaire, QUARTIS Questionnaire sur l’Allergie Respiratoire Traitée par Immunothérapie Sublinguale, SLIT sublingual immunotherapy